Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Animal Safety: $58.5 million compared to the $53.54 million average estimate based on three analysts. The reported number represents a change of -8.1% year over year.
• Revenues- Food Safety: $166.8 million compared to the $158.44 million average estimate based on three analysts. The reported number represents a change of +3.1% year over year.
• Revenues- Animal Safety- Life Sciences: $1.8 million versus the two-analyst average estimate of $1.69 million. The reported number represents a year-over-year change of +10%.
• Revenues- Animal Safety- Veterinary Instruments & Disposables: $15.8 million versus the two-analyst average estimate of $15.6 million. The reported number represents a year-over-year change of -2.8%.
• Revenues- Animal Safety- Animal Care & Other: $7 million versus $7.03 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -9.1% change.
• Revenues- Food Safety- Genomics Services: $6.6 million compared to the $11.75 million average estimate based on two analysts. The reported number represents a change of +4.3% year over year.
• Revenues- Animal Safety- Genomics Services: $17.2 million versus the two-analyst average estimate of $4.07 million. The reported number represents a year-over-year change of +4.1%.
• Revenues- Food Safety- Bacterial & General Sanitation: $46.7 million versus $42.96 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
• Revenues- Food Safety- Natural Toxins & Allergens: $19.2 million versus the two-analyst average estimate of $18.47 million. The reported number represents a year-over-year change of +3.3%.

View all Key Company Metrics for Neogen here>>>

Shares of Neogen have returned +1% over the past month versus the Zacks S&P 500 composite's -1.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research